Clincosm LogoSign in Get a demo

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Sponsor
Ruhr University of Bochum (Other)
Overall Status
Completed
CT.gov ID
NCT01482260
Collaborator
(none)
21
Enrollment
1
Location

Study Details

Study Description

Brief Summary

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Biopsy

Detailed Description

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Study Design

Study Type:
Observational
Actual Enrollment :
21 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi
Study Start Date :
Dec 1, 2011
Actual Primary Completion Date :
Jan 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Primary Cutaneous Malignant Melanoma

Procedure: Biopsy
Biopsy
Cutaneous Malignant Melanoma Metastases

Procedure: Biopsy
Biopsy
Benign Melanocytic Nevi

Procedure: Biopsy
Biopsy

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Primary Cutaneous Malignant Melanoma

    • Cutaneous Malignant Melanoma Metastases

    • Benign Melanocytic Naevi

    Exclusion Criteria:
    • Other Skin Cancer than Primary Cutaneous Malignant Melanoma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum Bochum NRW Germany 44791

    Sponsors and Collaborators

    • Ruhr University of Bochum

    Investigators

    • Study Director: Falk G Bechara, PD Dr., Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
    • Study Chair: Peter Altmeyer, Prof. Dr., Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Sand, Principal Investigator, Ruhr University of Bochum
    ClinicalTrials.gov Identifier:
    NCT01482260
    Other Study ID Numbers:
    • microRNA5
    First Posted:
    Nov 30, 2011
    Last Update Posted:
    Nov 6, 2012
    Last Verified:
    Nov 1, 2012
    Additional relevant MeSH terms:
    Melanoma
    Skin Neoplasms

    Study Results

    No Results Posted as of Nov 6, 2012